title: [Acceleration of ATP-induced contraction in the obstructed bladder of the rat].
abstract: BACKGROUND
  Detrusor instability is one of the most common problems in patients with lower urinary tract obstructive diseases, such as benign prostatic hyperplasia. Adenosine triphosphate (ATP) has been associated as a neuronal component in the detrusor instability.
  
  
  METHODS
  Ninety-six female Splague-Dawley rats were studied. Outflow obstructions were created by ligature of the urethra over which a catheter was placed. Changes in the bladder capacity, and an isovolumetric contractile response to pharmacologic antagonists were studied in the obstructed rats for a period of from one day to four weeks.
  
  
  RESULTS
  The bladder capacity of rats obstructed for four weeks increased significantly. Maximum bladder contraction pressure with the use of atropine medication was inhibited in 60 percent and, 30 percent of in the control group, respectively. The inhibitory effect of the maximum bladder contraction pressure by the pyridoxalphosphate-6-azophenyl-2', 4'-disulphonate (PPADS) dosage after the atropine dosage was not recognized it in the control group, but the effect was recognized powerfully in the obstructed group.
  
  
  CONCLUSIONS
  In the obstructed bladder rat, strong rise of the bladder contraction by P2X receptor with a lower urinary obstruction was accepted, and that result reflects positively. Therefore, it was guessed that the result was an end of the compensatory mechanism of unstable bladder.
authors.affiliation: Department of Urology, Akita University School of Medicine.
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Wada
authors.forename: Ryo
authors.initials: R
authors.lastname: Otomo
authors.forename: Naotake
authors.initials: N
authors.lastname: Shimoda
authors.forename: Shigeru
authors.initials: S
authors.lastname: Sato
authors.forename: Kazunari
authors.initials: K
authors.lastname: Sato
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Kato
mesh_terms: D000255:Adenosine Triphosphate / Q000494:pharmacology*; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D005260:Female; D008365:Manometry; D009119:Muscle Contraction / Q000187:drug effects*; D011732:Pyridoxal Phosphate / Q000031:analogs & derivatives* / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018048:Receptors, Purinergic P2 / Q000502:physiology*; D058469:Receptors, Purinergic P2X; D001743:Urinary Bladder / Q000503:physiopathology*; D001748:Urinary Bladder Neck Obstruction / Q000503:physiopathology*; D014554:Urination
chemical_list: D018048:Receptors, Purinergic P2; D058469:Receptors, Purinergic P2X; C077792:pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid; D011732:Pyridoxal Phosphate; D001285:Atropine; D000255:Adenosine Triphosphate